2018

CCM Duopharma Registers Double Digit Top and Bottom Line Growth in First Quarter 2018

Kuala Lumpur – CCM Duopharma Biotech Berhad (CCM Duopharma) recorded a 10.14 per cent growth in Revenue for the first quarter ended March 31, 2018 to RM133.26 billion from RM120.99 million in the same quarter last year. The Group’s Profit before Tax for the first quarter rose 18.60 per cent to RM13.26 million from RM11.18 million in the same period last year while Profit after Tax jumped 23.54 per cent to RM10.65 million from RM8.62 million in the previous year.

Hard Work Pays Off for Winners of The MPS-CCM Duopharma 2017 Gold Medal Award

Imagine a crowd of over 500 applauding, giving you their utmost respect the moment you step on a stage. You are presented with a prestigious award sought after by many budding pharmacists. However, not everyone knows the sheer grit and determination that ultimately led to the success.

Championing Autism Awareness With RM125,000 Worth of Specially Made Craft Items

Kuala Lumpur APRIL 30, 2018 – Handicraft made with love by children with autism will be showcased throughout Malaysia, thanks to Champs, Malaysia’s largest vitamin brand for children which is collaborating with the National Autism Society of Malaysia (NASOM) to create greater awareness and acceptance of autism, besides enabling the latter’s products to be appreciated by a wider market.

CCM Duopharma Raises Funds to Aid Chronic Kidney Patients

Kuala Lumpur April 25, 2018 – CCM Duopharma Biotech Berhad (CCM Duopharma) has raised RM5,000 in funds, through its “Wear Green for Charity” campaign, for the MAA Medicare Charitable Foundation which offers subsidised dialysis treatment to needy patients who are suffering from chronic kidney disease.

Duopharma Sets to be at The Forefront of Effervescent Manufacturing With New RM7 Million Plant

Bangi APRIL 3, 2018 – CCM Duopharma Biotech Berhad (Duopharma) expects its newly completed Effervescent plant in Bangi, the country’s first ever such facility, to put the Company at the forefront of technology development in manufacturing high-quality pharmaceutical products using Effervescent technology that offers advantages over conventional manufacturing of healthcare products.

Duopharma Signs Corruption-Free Pledge

KUALA LUMPUR – CCM Duopharma Biotech Berhad (Duopharma) has become the country’s first pharmaceutical company to sign the Corruption-Free Pledge in conjunction with the Malaysian Anti Corruption Commission (MACC).

Duopharma’s Sponsorship of Drama Series Boosts Sales of Flavettes Effervescent Vitamin C

Kuala Lumpur – Popularity of CCM Duopharma Biotech Berhad (Duopharma) sponsored drama series titled ‘Lafazkan Kalimah Cintamu’ has boosted sales of Flavettes Effervescent significantly due to the drama’s high rating and trending on the social media recently.

Mufti Witnesses Duopharma’s Effort in Intensifying Halal Integrity

Bangi, Selangor – CCM Duopharma Biotech Berhad’s (Duopharma) effort in intensifying its Halal integrity in the Halal pharmaceutical sector was further endorsed via the visit of Datuk Dr. Zulkifli Bin Mohamad Al-Bakri, Mufti of the Federal Territory, to its manufacturing plant located in Bangi recently.

Duopharma Announces Bonus Issue to Shareholders

Kuala Lumpur, February 27 2018 – CCM Duopharma Biotech Berhad (Duopharma) has proposed a bonus issue of up to 371,945,333 new ordinary shares on the basis of four (04) bonus shares for every three (03) existing shares, reflecting the company’s stronger fundamentals after it completed its demerger exercise earlier this year. Its Group Managing Director, Leonard Ariff Abdul Shatar said the bonus issue is aimed at rewarding existing shareholders for their loyalty and continuous support as well as increasing the share capital of the company to a level that will better reflect the current scale of operations and assets employed by Duopharma and its subsidiaries. In the statement to the local bourse today, Duopharma also announced that it is declaring its final dividend of six (06) sen per share and the Company is proposing to undertake the Proposed Dividend Reinvestment Plan (DRP), whereby the shareholders will be given the option to elect to reinvest the whole or part of the dividend into new ordinary shares of Duopharma.


Duopharma Announces Bonus Issue to Shareholders

Kuala Lumpur, February 27 2018 – CCM Duopharma Biotech Berhad (Duopharma) has proposed a bonus issue of up to 371,945,333 new ordinary shares on the basis of four (04) bonus shares for every three (03) existing shares, reflecting the company’s stronger fundamentals after it completed its demerger exercise earlier this year.